Science Explorer Interactive view Map
Topic · Pharmacology

Pharmacology and Obesity Treatment

Pharmacology and Obesity Treatment is a research topic within Pharmacology. Science Explorer counts 25k research works in it since 1950. 15.3% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the pharmacological management of obesity, including the use of anti-obesity drugs, clinical trials evaluating their efficacy and safety, and the impact on weight loss. It covers a wide range of medications such as sibutramine, orlistat, and ephedra alkaloids, as well as their associated adverse events and lipase inhibitors.

  • Obesity
  • Pharmacotherapy
  • Weight Loss
  • Anti-Obesity Drugs
  • Clinical Trials
  • Adverse Events
  • Lipase Inhibitors
  • Sibutramine
  • Orlistat
  • Ephedra Alkaloids
Research works
25k
fractional, since 1950
In the world top 10%
3.9k
per year above
Top-10% rate
15.3%
share of its works in the world top 10%
Growth, 2013–17 → 2018–22
+9%
the tick is no change

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Pharmacology and Obesity Treatment research?

By volume, the United States and India publish the most (882 and 405 works in 2022–2025).

By volume, 2022–2025

  1. 1 United States 882 works
  2. 2 India 405 works
  3. 3 China 230 works
  4. 4 United Kingdom 141 works
  5. 5 Brazil 133 works
  6. 6 Italy 127 works
  7. 7 Germany 125 works
  8. 8 Spain 114 works
  9. 9 Poland 94 works
  10. 10 South Korea 91 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 37.7%India: 17.3%China: 9.8%United Kingdom: 6.0%6 others listed: 29.2%38%largest
United States882 · 37.7%India405 · 17.3%China230 · 9.8%United Kingdom141 · 6.0%6 others listed684 · 29.2%

Shares of the rows listed above, not of the whole node.

Which institutions lead Pharmacology and Obesity Treatment research?

By volume in 2022–2025, National Institute of Ayurveda publishes the most Pharmacology and Obesity Treatment research, followed by Harvard University and Eli Lilly (United States).

By volume, 2022–2025

  1. 1 National Institute of AyurvedaIndia 14 works
  2. 2 Harvard UniversityUnited States 12 works
  3. 3 Eli Lilly (United States)United States 11 works
  4. 4 Johns Hopkins UniversityUnited States 11 works
  5. 5 University of TorontoCanada 10 works
  6. 6 Government Ayurvedic College and HospitalIndia 10 works
  7. 7 Yale UniversityUnited States 10 works
  8. 8 University of MosulIraq 10 works
  9. 9 Brigham and Women's HospitalUnited States 9 works
  10. 10 Massachusetts General HospitalUnited States 8 works

Who are the leading researchers in Pharmacology and Obesity Treatment?

The most-cited researchers publishing on Pharmacology and Obesity Treatment include Deepak L. Bhatt.

  1. 1 Deepak L. Bhatt United States 4.2k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

Where is Pharmacology and Obesity Treatment research done?

The largest centres of Pharmacology and Obesity Treatment research in 2022–2025 are New York (United States), London (United Kingdom), Boston (United States) and Seoul (South Korea).

Largest cities, 2022–2025

  1. 1 New York United States 42 works
  2. 2 London United Kingdom 38 works
  3. 3 Boston United States 38 works
  4. 4 Seoul South Korea 37 works
  5. 5 Beijing China 35 works
  6. 6 New Delhi India 32 works
  7. 7 Madrid Spain 30 works
  8. 8 Paris France 28 works
  9. 9 Moscow Russia 27 works
  10. 10 Rome Italy 24 works
See Pharmacology and Obesity Treatment on the map

Where is the best place to study Pharmacology and Obesity Treatment?

Among universities, judged by research, National Institute of Ayurveda, Harvard University and University of Toronto score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 23.0667%fractional works in this node (log) →share in the world top 10% →National Institute of Ayurveda: 14, 1.2%Harvard University: 12, 40.0%University of Toronto: 10, 32.5%Johns Hopkins University: 11, 30.4%Yale University: 10, 26.8%University of Mosul: 10, 7.5%Harvard UniversityUniversity of TorontoJohns Hopkins Univer…National Institute o…
above the meannear itbelow it

One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.

#UniversityScoreTop 10%SpecialisationWorksGrowth
1 National Institute of AyurvedaIndia 60.81.2%66.9×14 +142.2%
2 Harvard UniversityUnited States 58.240.0%2.6×12 +0.4%
3 University of TorontoCanada 45.432.5%2.0×10 +14.9%
4 Johns Hopkins UniversityUnited States 43.030.4%2.8×11 -16.1%
5 Yale UniversityUnited States 37.426.8%2.7×10 +2.0%
6 University of MosulIraq 36.17.5%7.2×10 —

Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.

Is Pharmacology and Obesity Treatment research growing?

Output in 2018–2022 was 9% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Pharmacology and Obesity Treatment.

19801990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.